From the Podium to Practice: Translating Emerging Transthyretin amyloid cardiomyopathy (ATTR-CM) Evidence Across Underserved and Underrecognized Populations | ESC Heart Failure 2026

From the Podium to Practice: Translating Emerging Transthyretin amyloid cardiomyopathy (ATTR-CM) Evidence Across Underserved and Underrecognized Populations | ESC Heart Failure 2026 is organized by Iridium Continuing Education, Global Education Group.

Release: 07/02/2026
Expiration: 07/02/2027

Program Overview:
This mobile-first microlearning module reviews key updates in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ESC Heart Failure 2026, with a focused emphasis on underrecognized hereditary ATTR-CM and the p.Val142Ile (V142I) variant. Through interactive evidence reviews, congress data interpretation, and case-based decision-making, learners will examine emerging findings related to disease recognition, biomarker stabilization, outpatient worsening heart failure events, and variant-specific treatment considerations across approved disease-modifying therapies.

Designed for busy clinicians, this interactive microlearning activity integrates late-breaking congress evidence with practical clinical application to support earlier recognition of ATTR-CM in historically underserved and underdiagnosed populations, particularly African American patients with hereditary disease. Learners will engage with evolving therapeutic data, interpret clinically relevant outcomes, and apply evidence-informed strategies to diagnosis, treatment selection, and longitudinal management in real-world practice.

Learning Objectives:
Upon completion of this activity, the participant should be able to:

• Apply structured diagnostic and genetic screening approaches for patients with suspected hereditary ATTR-CM, including those with the p.Val142Ile (V142I) variant
• Differentiate clinical red flags and diagnostic features suggestive of ATTR-CM in underrecognized patient populations presenting with HFpEF, ventricular wall thickening, or unexplained heart failure symptoms
• Interpret emerging ESC Heart Failure 2026 data related to ATTR-CM disease-modifying therapies, including biomarker, heart failure, and functional outcome measures
• Evaluate evolving evidence across TTR stabilizer and silencer therapies to support individualized treatment selection and longitudinal management strategies in ATTR-CM
• Integrate late-breaking congress evidence into clinical decision-making for patients with hereditary and variant-associated ATTR-CM